Pharma Unit Loses Licence Over Spurious Cardiac Injection in Export Consignment
A pharmaceutical manufacturing unit in Solan, Himachal Pradesh, has had its licence revoked after a spurious cardiac injection was discovered in an export consignment. The action was taken by the state drug regulatory authority following a detailed investigation.
The incident came to light when routine quality checks on an export shipment revealed the presence of a counterfeit cardiac injection. The drug controller's office immediately suspended the unit's licence pending further inquiry. Officials confirmed that the spurious injection could have posed serious health risks if administered.
According to sources, the unit was manufacturing the injection for export to several countries. The regulatory body has sealed the facility and initiated legal proceedings against the company's management. Samples have been sent for further analysis to determine the extent of contamination.
This development has raised concerns about quality control in pharmaceutical exports. The state government has assured strict action against any lapses. Industry experts emphasize the need for enhanced surveillance to prevent such incidents and maintain India's reputation as a reliable pharmaceutical supplier.
The unit's licence revocation is a significant step in ensuring compliance with drug manufacturing standards. Authorities are also investigating whether other products from the same facility were affected. The company faces potential penalties and possible blacklisting from future exports.
